Search

According to a report by Transparency Market Research, the global injectable cytotoxic drug market is projected to grow at a moderate CAGR of 6.8% and reach USD 38.2 billion by 2034. The demand for these drugs is driven by the prevalence of cancer and the need for therapeutics and treatments for cancer patients. Additionally, the increasing cases of rheumatoid arthritis and multiple sclerosis are contributing to the demand for advanced therapeutics. The introduction of new drugs in the market is gaining traction due to the rising demand worldwide. [Extracted from the article]

A recent study conducted by the Department of Chemistry has highlighted the limitations of testing drugs for pancreatic cancer in 2D cell models. The researchers found that treatment with 5-fluorouracil (5-FU) in 2D and 3D culture models of colorectal cancer (CRC) and pancreatic ductal adenocarcinomas (PDAC) resulted in different responses regarding growth inhibition. The study suggests that screening with longer exposure and several cycles of treatment in 3D models may provide a more reliable way to assess drug sensitivity. This research provides valuable insights into improving in vitro drug screening methods for pancreatic cancer. [Extracted from the article]

A recent patent application from Texas A&M University System describes the development of endolysosomal targeting conjugates, which are engineered proteins that enhance the delivery of cargo molecules to specific cells. These conjugates consist of a targeting component and a cargo component, and they are designed to deliver cargo molecules to the endolysosomal compartment of target cells. The technology has potential applications in cancer treatment and tumor imaging. Additionally, a recent study conducted at Texas A&M University System found that nanobodies, small antibodies that can be engineered to target specific cancer cells, were effective in delivering cytotoxic drugs directly to cancer cells, leading to improved treatment outcomes. This study demonstrates the potential of nanotechnology in oncology and offers new possibilities for targeted cancer therapies. [Extracted from the article]

A report from Haryana, India discusses the use of hydrogel-bound cytotoxic drug delivery systems for breast cancer treatment. The report highlights the drawbacks of conventional chemotherapeutic agents, which can harm healthy cells along with cancer cells. The researchers propose the use of smart hydrogels that release cytotoxic drugs in response to specific stimuli, such as pH or temperature, to improve drug efficacy and reduce adverse effects. The study concludes that stimuli-sensitive hydrogels show promise for delivering cytotoxic drugs to breast cancer tumor microenvironments. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the limitations of testing drugs in 2D cancer models and the importance of using appropriate growth inhibition analysis. The study compares the response to treatment with 5-fluorouracil (5-FU) in 2D and 3D culture models of colorectal cancer (CRC) and pancreatic ductal adenocarcinomas (PDAC). The results show that the 3D models suggest a more reliable way to assess drug sensitivity, as they exhibit significant growth inhibition at clinically achievable concentrations after two cycles of treatment, while the 2D models do not. The study emphasizes the need for longer exposure and multiple treatment cycles in 3D models to better replicate the in vivo tumor environment. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A recent study conducted at the Hudson Institute of Medical Research in Victoria, Australia, explored the use of EGFR-targeted nanocells in the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). The study involved 25 patients who had exhausted all other treatment options. The results showed that the nanocells provided significant overall survival (OS) and minimal side effects, with a median OS of 6.9 months for patients who completed one treatment cycle. The researchers concluded that super-cytotoxic drugs delivered via nanocells can safely treat advanced PDAC and overcome multi-drug resistance. [Extracted from the article]

A study conducted at St. Louis Hospital in Paris, France, examined the risk of 5-fluorouracil (5-FU) contamination for nurses when disconnecting the infusion line of an elastomeric pump. The study compared three configurations: standard Male and Female Luer lock, a needle-free connector (NFC) and a Male Luer lock, and a closed-system transfer device (CSTD), Qimono(R). The research found that the use of Qimono(R) significantly reduced 5-FU contamination when disconnecting infusion lines, unlike NFC and standard Luer lock. The study suggests that the use of a closed-system transfer device can help reduce occupational exposure to cytotoxic drugs. [Extracted from the article]

In one embodiment, the cytotoxic polypeptide that converts a prodrug to a cytotoxic drug is selected from the group consisting of a polypeptide having cytosine deaminase activity, a polypeptide having thymidine kinase activity and a combination thereof. A recombinant vector comprising: (a) a polynucleotide encoding a chimeric antigen receptor (CAR); and (b) a polynucleotide comprising at least one miRNA targeting sequence, wherein (a) and (b) are linked on the same polynucleotide. The recombinant retroviral particle of claim 18, wherein the polypeptide has thymidine kinase (TKO) activity or cytosine deaminase (CD) activity. "The disclosure provides a recombinant vector comprising (a) a polynucleotide encoding a chimeric antigen receptor (CAR); and (b) polynucleotide comprising at least one miRNA targeting sequence, wherein (a) and (b) are linked on the same polynucleotide. [Extracted from the article]

The endolysosomal targeting conjugate has a targeting component that includes an antibody, an antibody fragment, an antibody domain, a nanobody, a protein, a protein fragment, or a protein domain, wherein the targeting component is configured to bind to a cell surface molecule of a target cell. The endolysosomal targeting conjugate also has a cargo component that includes a cargo molecule conjugated to an antibody, an antibody fragment, an antibody domain, a nanobody, a protein, a protein fragment, or a protein domain. The endolysosomal targeting conjugate also has a cargo component that includes a cargo molecule conjugated to an antibody, an antibody fragment, an antibody domain, a nanobody, a protein, a protein fragment, or a protein domain. [Extracted from the article]

Breast Cancer, Cancer, Cytotoxic Drug, Drug Delivery, Drug Delivery Systems, Drugs and Therapies, Health and Medicine, Oncology, Women's Health Keywords: Breast Cancer; Cancer; Cytotoxic Drug; Drug Delivery; Drug Delivery Systems; Drugs and Therapies; Health and Medicine; Oncology; Women's Health EN Breast Cancer Cancer Cytotoxic Drug Drug Delivery Drug Delivery Systems Drugs and Therapies Health and Medicine Oncology Women's Health 1130 1130 1 05/22/23 20230526 NES 230526 2023 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on breast cancer is the subject of a new report. [Extracted from the article]

All studies reporting the outcomes relevant to drug-compounding robots such as accuracy, safety, and drug contamination were included. Keywords: Cytotoxic Drug; Drugs and Therapies; Emerging Technologies; Health and Medicine; Machine Learning; Nano-robot; Risk and Prevention; Robot; Robotics; Robots EN Cytotoxic Drug Drugs and Therapies Emerging Technologies Health and Medicine Machine Learning Nano-robot Risk and Prevention Robot Robotics Robots 2090 2090 1 03/23/23 20230317 NES 230317 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on robotics is now available. Robot, Robotics, Cytotoxic Drug, Robots, Drugs and Therapies, Emerging Technologies, Health and Medicine, Machine Learning, Risk and Prevention, Nano-robot. [Extracted from the article]